Abstract
Advanced fibrosis and portal hypertension are critical determinants of mortality in alcoholic hepatitis (AH). This study identifies Lipocalin 2 (LCN2) as a functional regulator of these processes. We found that hepatic LCN2 expression is markedly increased in AH patients, correlating with disease severity and portal pressure. Mechanistically, LCN2 promotes fibrosis and vasoconstriction through a HIF1A-EDN1 signaling axis. LCN2 knockout mice demonstrated significant protection against experimental liver fibrosis, suggesting LCN2 as a potential therapeutic target.
Introduction
Alcoholic hepatitis (AH) is a severe clinical syndrome characterized by acute liver failure and high short-term mortality. The prognosis is heavily influenced by the degree of liver fibrosis and the severity of portal hypertension—elevated blood pressure within the portal venous system. Despite their clinical importance, the molecular drivers of these pathologies in AH remain poorly understood, and current treatments like corticosteroids offer limited efficacy. This research investigates the role of Lipocalin 2 (LCN2), an innate immune protein, in the progression of AH.
Methods
The study utilized a translational approach combining human clinical data with experimental models:
- Human Clinical Analysis: Liver biopsies and serum samples from the InTeam Consortium were analyzed. Gene expression was mapped using RNA-sequencing and microarrays (GEO: GSE130123, GSE130128).
- Animal Models: $Lcn2^{-/-}$ (knockout) and wild-type mice were subjected to chronic $CCl_4$ exposure and an "ethanol plus binge" model to simulate liver injury and fibrosis.
- In Vitro Mechanistic Studies: Human primary hepatocytes and Hepatic Stellate Cells (HSCs) were used to trace signaling pathways via LCN2 overexpression, siRNA knockdown, and ChIP-qPCR.
Results
LCN2 is Markedly Elevated in Alcoholic Hepatitis
Analysis of human liver tissue revealed that LCN2 expression is uniquely and significantly upregulated in AH compared to healthy controls, Hepatitis C (HCV), and cirrhosis. While LCN2 is typically restricted to immune cells in healthy livers, it is "reprogrammed" for mass production by hepatocytes in the context of AH.
Correlation with Disease Severity and Portal Hypertension
Hepatic LCN2 levels showed strong positive correlations with clinical severity scores (MELD and ABIC). Crucially, LCN2 expression correlated with the Hepatic Venous Pressure Gradient (HVPG), a direct measure of portal hypertension, and with the expression of key fibrotic markers such as $COL1A1$ and $TIMP1$.
LCN2 Deficiency Protects Against Fibrosis
In experimental models, $Lcn2^{-/-}$ mice were significantly protected from liver fibrosis induced by $CCl_4$ or ethanol. These mice exhibited reduced collagen accumulation and lower expression of pro-fibrotic genes compared to wild-type controls. In vitro experiments confirmed that recombinant LCN2 directly stimulates collagen production in human Hepatic Stellate Cells.
Discussion
The study uncovers the LCN2-HIF1A-EDN1 molecular axis as a driver of liver pathology. LCN2 induces HIF1A, which in turn upregulates Endothelin 1 (EDN1), a potent vasoconstrictor that increases portal pressure. Simultaneously, LCN2 acts as a pro-fibrotic agent by activating stellate cells.
While mouse models do not perfectly replicate the full spectrum of human AH, the strong correlation in human tissue suggests LCN2 is a functional driver rather than a passive biomarker. As a secreted protein, LCN2 represents a promising "druggable" target for neutralizing therapies aimed at reducing fibrosis and managing portal hypertension in severe liver disease.
Summary updated